Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen is a component of a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. The key active ingredient is a recombinant form of the factor H binding protein (fHBP), specifically the LP2086 lipoprotein, which exists in two subfamilies to ensure broad protection against diverse strains. The mechanism of action involves eliciting antibodies that target fHBP on the surface of N. meningitidis, leading to complement-mediated bactericidal activity and prevention of infection. This approach was developed due to poor immunogenicity from polysaccharide-based vaccines and limited strain coverage from outer membrane vesicle vaccines[1][2][5][7]. The bivalent formulation (as in Trumenba) includes two variants from each fHBP subfamily for broader coverage[2][7].
- Brand names
- Trumenba
- Other names
- bivalent rLP2086factor H binding protein vaccine (fHBP vaccine)Neisseria meningitidis group B recombinant LP2086 B01 protein variant antigen
02
Targets
fHbp (Factor H-binding protein)
Beyond the preview
Go deeper on Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen.